Back to search

Article

Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting PI3K/AKT Pathway and Activating AMPK/ROS Pathway

2020-12-02

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Ovarian cancer is the most lethal female genital malignancy. Though cisplatin is still the first-line chemotherapy to treat ovarian cancer patients with debulking surgeries, its efficacy is limited due to the high-incidence of cisplatin resistance. ATP citrate lyase (ACLY) has been proved to be a key metabolic enzyme and was related to poor prognosis in various...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a81be9e2-209d-5ebf-b539-464b0c63d97a
DOI
10.21203/rs.3.rs-117480/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting PI3K/AKT Pathway and Activating AMPK/ROS PathwayDOI 10.21203/rs.3.rs-117480/v1
Select a neighboring publication to make it the new centre.